Meet Jeff Smith, the hedge-fund investor taking on PfizerStarboard Value's $1 billion investment in Pfizer signals potential strategic changes, aiming to enhance operational efficiency and profitability.
Activist investor Starboard has just informed Pfizer it has taken a significant stakeStarboard Value has taken a significant stake in Pfizer amidst falling stock prices since the COVID-19 vaccine rollout.
Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysisActivist investor Starboard Value's proxy fight against Pfizer has intensified, with claims of CEO Bourla's underperformance amid shifting loyalties from former Pfizer executives.
Meet Jeff Smith, the hedge-fund investor taking on PfizerStarboard Value's $1 billion investment in Pfizer signals potential strategic changes, aiming to enhance operational efficiency and profitability.
Activist investor Starboard has just informed Pfizer it has taken a significant stakeStarboard Value has taken a significant stake in Pfizer amidst falling stock prices since the COVID-19 vaccine rollout.
Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysisActivist investor Starboard Value's proxy fight against Pfizer has intensified, with claims of CEO Bourla's underperformance amid shifting loyalties from former Pfizer executives.